Sharapova targets April return after doping ban reduced

The Court of Arbitration for Sport (CAS) cut Sharapova's ban to 15 months saying she was not an "intentional doper", after the 29-year-old tested positive for the banned medication meldonium during January's Australian Open -- throwing her glittering, money-spinning career into serious jeopardy.

"I’ve gone from one of the toughest days of my career last March, when I learned about my suspension, to now, one of my happiest days, as I found out I can return to tennis in April," said Sharapova, who has racked up 35 WTA singles titles and more than $36 million in career earnings.

An April return means she would be able to compete at the French Open in May-June next year -- she is a two-time champion at Roland Garros.

Sharapova, whose ferocity on court, business acumen and glamorous looks all combined to make her a marketing juggernaut, was hit with a two-year ban by an independent tribunal appointed by the International Tennis Federation (ITF).

Reducing the ban, the Lausanne-based CAS "found that Ms Sharapova committed an anti-doping rule violation and that while it was with 'no significant fault', she bore some degree of fault, for which a sanction of 15 months is appropriate".

And in the panel's more detailed, formal decision, it said significantly: "Under no circumstances, therefore, can the player be considered to be an 'intentional doper'."

Sharapova openly admitted she had been taking meldonium, an over-the-counter drug made in Latvia, for 10 years to help treat illnesses, a heart issue and a magnesium deficiency.

She always maintained that it had entirely escaped her attention that the product had been added to the banned substance list published by the World Anti-Doping Agency (WADA) on January 1, just before the Australian Open.

"I have taken responsibility from the very beginning for not knowing that the over-the-counter supplement I had been taking for the last 10 years was no longer allowed," Sharapova said in her Facebook post Tuesday.

"But I also learned how much better other (sports) Federations were at notifying their athletes of the rule change, especially in Eastern Europe, where Mildronate (the trade name of meldonium) is commonly taken by millions of people."

Sharapova added: "Now that this process is over, I hope the ITF and other relevant tennis anti-doping authorities will study what these other Federations did, so that no other tennis player will have to go through what I went through."

Steve Simon, CEO of the WTA, said he backed the CAS decision.

"We are pleased that the process is now at completion and can look forward to seeing Maria back on court in 2017," he added.

'Counting the days'

Sharapova, who off the court enjoyed successful ventures such as her "Sugarpova" line of candy, helping her amass a fortune estimated at $200 million, said she was itching to get back on court.

"I’m coming back soon and I can’t wait!" she said.

"In so many ways, I feel like something I love was taken away from me and it will feel really good to have it back.

"Tennis is my passion and I have missed it. I am counting the days until I can return to the court."

Russian Sports Minister Vitaly Mutko told TASS news agency: "I'm very happy for Maria, although I think that CAS should have fully lifted her suspension for a drug like meldonium."

Sharapova was intially prescribed meldonium a year after winning Wimbledon as a 17-year-old by a Russian doctor in Moscow to boost her immune system.

She burst onto the tennis scene by stealing hearts and that title at Wimbledon in 2004 before going on to clinch the US Open in 2006, the Australian Open in 2008 and the French Open in 2012 and 2014.

The chairman of Sharapova's tennis racquet manufacturer and sponsor, Head, was emphatic in his criticism of rulings on meldonium.

"We are very proud to have stood by Maria for the right reasons throughout these difficult and testing times," said Johan Eliasch.